Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Rhett Schiffman?

Rhett M. Schiffman

Chief Medical Officer

Neurotech S.A

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Neurotech S.A

Background Information

Employment History

Chief Medical Officer and Executive Vice President Research and Development

Envisia Therapeutics


Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology

Allergan , Inc.


Affiliations

Glaucoma Research Foundation

Board Member


GRFS LLC

Board Member


Education

B.S.

Bioengineering

Columbia University


M.D.

University of Juarez , Mexico


MS


Master's degrees

Clinical Research Design and Statistical Analysis and in Health Services Administration

University of Michigan


Web References(38 Total References)


MANAGEMENT | Envisia

www.envisiatherapeutics.com [cached]

Rhett M. Schiffman, M.D.
Chief Medical Officer & Executive Vice President, Research & Development Dr. Rhett Schiffman is Senior Vice President of Development and Chief Medical Officer at Envisia. Previously, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program through phase 1/2 clinical trials. Prior to Neurotech, he was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he played a key role in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®. Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products. Dr. Schiffman received his B.S. in Bioengineering from Columbia University and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital in Michigan and is Board Certified in both specialties and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health. He has served on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine where he sees patients and teaches residents.


ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia Envisia ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER Envisia Recruits Top Talent to Help Advance Promising Pipeline RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


www.pappasventures.com

RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development.
Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology.


ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER Envisia Recruits Top Talent to Help Advance Promising Pipeline RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


Executive Team & Board Of Directors | Neurotech Pharmaceuticals

www.neurotechusa.com [cached]

Chief Medical Officer Rhett Schiffman
Rhett Schiffman, M.D., M.S., M.H.SA Chief Medical Officer Dr. Schiffman joined Neurotech as CMO in September 2013. Rhett Schiffman was most recently Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, where since 2001 he was instrumental in the global development and approval of many of ophthalmology's most successful products including Restasis®, Combigan®, Lumigan®, Acuvail® and Acular®, Zymaxid® and Zymar® and most recently, the Lumigan® and Ganfort® unit dose products. He also currently serves on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine. Dr. Schiffman received his B.S. in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital, is Board Certified in both and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory